Furthermore, clinical studies have shown that GPR30 overexpression is associated with the incidence of patients with poor prognosis of ovarian and endometrial cancer [8, 9], which suggests that GPR30 may play an important role in carcinogenesis. Here, GPER1 is linked to endometrial cancer.